Repros Therapeutics (RPRX -0.9%) says it will meet with the FDA in the second half of May to...

|About: Repros Therapeutics Inc. (RPRX)|By:, SA News Editor

Repros Therapeutics (RPRX -0.9%) says it will meet with the FDA in the second half of May to discuss Phase 3 trials for the company's Proellex treatment for uterine fibroids. Last week, Repros' shares surged on news that its Androxal Phase 3 program has been given a receipt of written guidance by the agency. (PR)